FDA Imposes Deadline on Synthetic Nicotine Products

Jul.15.2022
FDA Imposes Deadline on Synthetic Nicotine Products
FDA takes action on synthetic nicotine products; warns manufacturers illegal sales of non-tobacco e-cigarettes.

On Wednesday, the FDA Tobacco Products Center faced a deadline to take action on popular synthetic nicotine products. However, the agency did not take the strong action that lawmakers and anti-tobacco advocates had requested.


Electronic cigarette companies must submit their pre-market applications before May 14th in order to maintain their products on the market. Products that use synthetic nicotine in electronic cigarettes without FDA authorization must be removed from shelves before July 13th. On Wednesday, the FDA announced its so-called "first two warning letters" to manufacturers who have been illegally selling non-tobacco nicotine electronic cigarette products without authorization.


Synthetic nicotine is an attempt by the industry to evade FDA oversight by manufacturing nicotine in labs rather than sourcing it from tobacco, effectively putting it out of the agency's jurisdiction. However, the FDA stated before the law came into effect in April that the national spending package announced in March "clearly indicates that the FDA can regulate all tobacco products containing nicotine.


According to the FDA, letters were sent to AZ Swagg Sauce LLC and Electric Smoke Vapor House, which together have 10,000 products. The agency stated that both companies did not submit premarket applications by the deadline. Under the law, anyone manufacturing or selling "non-tobacco nicotine" must comply with FDA regulations, which include the requirement for FDA authorization, no sales to individuals under the age of 21, and no claims that their products are less harmful than cigarettes.


The US Food and Drug Administration (FDA) announced on Wednesday that it has sent 107 warning letters to retailers in the past two weeks, demanding that they refrain from selling synthetic nicotine products to minors.


According to Brian King, director of the Center for Tobacco Products, the FDA has been actively implementing key new laws regulating non-tobacco nicotine products since their passage. The warning letters announced today are just the beginning of our efforts to ensure compliance and enforcement. Over the coming weeks, we will continue to investigate companies that may be illegally marketing, selling, or distributing non-tobacco nicotine products and take appropriate action.


Starting Wednesday, any new synthetic nicotine products that have not been authorized for market by the FDA cannot be legally sold. The US Food and Drug Administration (FDA) has reported that it is currently processing over one million applications for synthetic nicotine products submitted by more than 200 manufacturers.


Anti-tobacco advocates say that the FDA's actions are insufficient.


This is not even a step forward, it's just them lifting their foot," said Erika Sward, National Assistant Vice President of Public Affairs for the American Lung Association. Taking action against retailers does not cut off the head of the beast.


Sward stated that all products should be taken down by Thursday with no reason for retention.


The FDA has not taken action against the popular disposable brand, Puff Bar, which offers a variety of flavors including mango, strawberry banana, and peach ice. The product has become a favorite among students in 2021, with over a quarter of high school students claiming Puff Bar as their go-to brand.


According to Sward, the deadline is crucial because it involves the most popular products and brands among children, including Puff Bar. "If the FDA is really going to take action to protect children, Puff Bar needs to be the starting point. We fully expect and hope to see Puff Bar removed from the market. I think it's clear that this is what Congress wants.


Puff Bar did not respond to this.


Republican Senator Susan Collins of Maine and Democratic Senator Dick Durbin of Illinois wrote a letter to the FDA, urging the agency to complete its work before the deadline. On Wednesday, Durbin criticized the agency in the Senate.


The FDA should protect all Americans, especially our children. I call on the FDA to ultimately regain their senses. Stand on the side of public safety, stand on the side of children, not on the side of tobacco companies. The FDA's legal department's actions are unimaginable. This is unsafe for the United States. This is unsafe for our future," he said.


The anti-tobacco organization expressed disappointment with the FDA's inaction.


Harold Wimmer, the President and CEO of the American Lung Association, stated that in March, Congress gave the FDA a clear deadline to regulate tobacco products made with synthetic nicotine. The law requires the FDA to take action and immediately remove these products from the market, using the necessary tools at their disposal.


In May, the FDA announced that it will not complete the review of all pre-market applications for electronic cigarette companies before June 2023, despite a court order to make a decision by that time. This marks a delay of nearly two years.


According to a national survey on youth tobacco use, over two million middle and high school students used e-cigarettes in 2021.


Wimmer stated, "The FDA's ongoing delay is putting more children at risk of addiction to these products. We urge the FDA to swiftly remove all synthetic nicotine products from the market and take strict enforcement measures.


Last week, after a temporary administrative halt was put in place by the US Appeals Court on June 24, the FDA announced that it was suspending its order to remove all Juul Labs' electronic cigarette products from store shelves. The agency cited "scientific issues" and stated that further review was warranted. Anti-tobacco organizations criticized the agency for making ambiguous statements.


The Biden administration has taken steps to curb smoking. In June, it announced plans to develop a proposed regulation that would establish a maximum nicotine level in cigarettes and other tobacco products.


In April, the FDA proposed a rule to ban menthol cigarettes and flavored cigars. A public hearing was held on this topic earlier this summer, and the agency is currently reviewing comments to ultimately determine the rule. However, tobacco companies are expected to file lawsuits in order to prevent the rule from going into effect.


I'm sorry, but I am an AI language model and I need the original text to provide a translation. Can you please provide the text?



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
Malaysia Reviews Possible Refund of $92 Million in Vape Taxes After Court Rules 2023 Nicotine Exemption Unlawful
Malaysia Reviews Possible Refund of $92 Million in Vape Taxes After Court Rules 2023 Nicotine Exemption Unlawful
Malaysia's Ministry of Finance said in a written parliamentary reply on November 17, 2026, that it was examining whether a court ruling concerning the country's 2023 liquid-nicotine exemption affected the legal basis for vape excise duties already collected. Royal Malaysian Customs Department records show that the government has collected RM377.08 million (approximately $92 million) in vape-related excise duties since May 2023, with the proceeds transferred to the federal Consolidated Fund. In May, the Kuala Lumpur High Court ruled that the 2023 decision to exempt liquid and gel nicotine used in vaping products from the Poisons List was unlawful. The government withdrew its appeal in August but has not decided whether the taxes should be refunded. The Finance Ministry is also seeking the Health Ministry's position on future vaping regulation.
Regulations
Nov.19
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26